The effect of lacosamide on calcitonin gene-related peptide serum level in episodic migraine patients: a randomized, controlled trial
ConclusionThe daily use of lacosamide 50 mg Bid for three months in episodic migraine patients was associated with a significant reduction in serum CGRP-LI, better clinical outcomes regarding frequency and duration of migraine attacks, and was well tolerated by patients. These results were derived from an open-label pilot study that need ed to be thoroughly investigated by a large-scale, randomized, double-blinded, placebo-controlled study.Trial registration: We registered our trial on ClinicalTrials.gov, named after"The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients," and with a clinical trial number (NCT05632133) —August 8, 2023.
Source: Acta Neurologica Belgica - Category: Neurology Source Type: research
More News: Brain | Clinical Trials | Egypt Health | Genetics | Headache | Ibuprofen | Migraine | Neurology | Pain | Statistics | Study